Amendment On Study Of Confidential Drug Pricing Deals: Rejected
The Senate rejected a proposed change to the budget resolution that would have required a government study of the economic effects of private or confidential drug pricing agreements between federal agencies and pharmaceutical manufacturers. The vote was 48 in favor and 50 against.
S.Con.Res. 33 · On the Amendment · Senate Vote 103 · Official title: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035. · Sponsored by Rep. Lindsey Graham
What This Vote Meant
A vote on a proposed change to the bill. Its stated purpose: To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
was a vote to make the change.
was a vote to reject the change.
This concurrent resolution sets the federal budget framework for fiscal year 2026 and budget levels through 2035, and directs four committees to draft reconciliation legislation adding no more than $70 billion to the deficit.
Drafted by AI from the official title and summary. Read more and check the source.
How Each Party Voted
2 Members Broke With Their Party
Members who voted differently from most of their own party.
2 Members Did Not Vote
D1 Democrat
R1 Republican
Full Roll Call
Voted Yea (48)
Voted Nay (50)
Did not vote (2)
- Introduced
- Committee
- Senate
- House
Tell The People Who Represent You What You Think About Budget And Spending
Three people in Congress vote on your behalf: one representative in the House and two senators. A call or a message from someone they represent is counted, and it takes two minutes.
We do not track you or sell your data. The lookup happens on your own device, and your ZIP code is only saved with us if you subscribe.